INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class
Debt / NOTE 2.000% 5/1
Market price (% of par)
99.45%
Total 13F principal
$211,575,000
Principal change
+$209,812,000
Total reported market value
$219,686,524
Number of holders
27
Value change
+$217,942,000
Number of buys
26

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q2 2019

As of 30 Jun 2019, INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 was held by 27 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $211,575,000 in principal (par value) of the bond. The largest 10 bondholders included FRANKLIN RESOURCES INC, Linden Advisors LP, HIGHBRIDGE CAPITAL MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, Graham Capital Management, L.P., LAZARD ASSET MANAGEMENT LLC, Polar Asset Management Partners Inc., Allianz Asset Management GmbH, and WELLINGTON MANAGEMENT GROUP LLP. This page lists 27 institutional bondholders reporting positions for the Q2 2019 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.